ClinicalTrials.gg
Enrolling by invitationNCT07504562Updated Jun 5, 2026

Knee Pain Ejiao Paste for Knee Osteoarthritis

A Phase 2 interventional study of Knee Pain Ejiao Paste and Knee Pain Ejiao-free Clear Paste in Knee Osteoarthritis, sponsored by ShuGuang Hospital. Enrolling by invitation at 2 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by ShuGuang Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.

Planned enrollment
71st of 115
60 · median 100
Started
2026
with 11 others
Phase 2
9 of 136
3 open now
Primary completion
2026-12
later than 18 of 31 live
Registered
125th of 136
by date

Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 71st largest by planned enrollment of the 115 interventional ones that give a count, is one of 12 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 18 of the 31 other live ones, and was the 125th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Osteoarthritis, Knee with a site in China, or all of them as a file.
02

Study summary

To explore the analgesic efficacy of Knee Pain Ejiao Paste in the treatment of knee osteoarthritis (Qi and Blood Deficiency Pattern) after 12 weeks, using an Ejiao-free clear paste as a parallel control and incorporating a synthetic external control.

Read the detailed description

Overall Design: This study employs a randomized, double-blind, internal and external dual-control clinical trial design. Trial Procedures: The trial consists of a screening/baseline period and a 12-week treatment period, with an End-of-Study (EOS) or End-of-Treatment (EOT) visit conducted after 12 weeks of administration. Randomization and Blinding: A stratified block randomization method will be used to assign participants to each group in a 1:1 ratio, with competitive enrollment across all centers and a double-blind design. External Control: Literature-based data. Data Collection: Electronic Data Capture (EDC) system and Electronic Patient-Reported Outcome (ePRO) system.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Knee Osteoarthritis
  • Qi and Blood Deficiency Pattern
  • Knee Pain Ejiao Paste
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meets the diagnostic criteria for knee osteoarthritis (OA), with unilateral or bilateral knee involvement
  2. Prior to randomization, the NRS pain score of the target knee joint ≥4, and the NRS score of the contralateral knee joint is not higher than that of the target knee joint; among the 5 pain items on the WOMAC, at least 1 item scores ≥40 mm
  3. (BMI) ≤32 kg/m²
  4. Meets the diagnostic criteria for Qi and Blood Deficiency Pattern
  5. Age between 40 and 75 years inclusive (40 years ≤ age ≤ 75 years), male or female
  6. The Kellgren-Lawrence grading of the target knee joint is grade I-III, and the Kellgren-Lawrence grading of the contralateral knee joint is not higher than that of the target knee joint (in cases of unilateral disease, the affected side is the target knee joint; in cases of bilateral disease, the target knee joint must satisfy the above criteria)
  7. Voluntarily participates in this clinical trial, provides , and signs the informed consent form

Exclusion criteria

Exclusion Criteria:

  1. Other conditions exist that may confound the assessment of function and pain in the target knee joint, such as: systemic diseases that may involve the joints (e.g., gouty arthritis, rheumatoid arthritis, etc.), chronic inflammatory or connective tissue diseases, neurological disorders, Paget's disease involving the knee, localized pain resulting from radicular lumbar compression, and any other conditions that may interfere with the efficacy assessment
  2. Use of other Chinese or Western medicines or therapies for osteoarthritis within one week prior to screening (excluding celecoxib tablets): such as non-steroidal anti-inflammatory drugs (excluding aspirin at no more than 325mg daily for cardiovascular disease prevention) , analgesics (including opioids, non-steroidal anti-inflammatory drugs, cyclooxygenase-2 (COX-2) inhibitors, tramadol, ketamine, clonidine, gabapentin, pregabalin and/or cannabinoids), or traditional Chinese medicine formulations with similar therapeutic indications to Knee Pain Ejiao Paste (i.e., those possessing qi-tonifying and blood-nourishing effects)
  3. Use within 4 weeks prior to screening of drugs that relieve osteoarthritis (OA) symptoms (such as glucosamine, chondroitin sulfate, diacerein, etc.), any nutritional supplements with potential activity on articular cartilage, systemic or drugs (subjects requiring only inhaled corticosteroids for asthma treatment may be enrolled)
  4. Receipt of biological products or intra-articular drug injection therapy (e.g., glucocorticoids, sodium hyaluronate, medical chitosan, growth factors, -rich plasma, stem cell therapy, etc.) within 3 months prior to screening
  5. Invasive procedures such as arthroscopy or lavage of the target knee joint within 6 months before screening or planned during the study period
  6. Previous or planned target knee joint replacement (partial or total), autologous osteochondral mosaicplasty, microfracture, meniscectomy, osteotomy or other surgery during the study period
  7. Planned change or new use of mobility aids (e.g., wheelchair, walker, cane or crutch) or need for lower limb prosthesis and/or structural knee brace during the study period
  8. Investigator-judged serious comorbid cardiovascular, cerebrovascular, gastrointestinal diseases, poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg), or other conditions that could affect the assessment of the product's efficacy and safety
  9. Laboratory abnormalities: (ALT) or aspartate aminotransferase (AST) >1.5 times the (ULN), or creatinine (Cr) >ULN
  10. Known or suspected allergy to the investigational product, rescue medication, or any of their components
  11. Pregnant or lactating women, or women of planning pregnancy from enrollment through 3 months after the end of the study
  12. Known or suspected history of alcohol or drug abuse
  13. Intellectual disability, psychosis, or neurosis
  14. Subjects who participated in any interventional drug clinical trial and received the investigational drug within 3 months prior to enrollment, or who are within 5 half-lives (whichever is longer) of any other clinical trial drug
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Knee Pain Ejiao Paste

    Knee Pain Ejiao Paste: Oral administration, 1 bag per dose, twice daily (20g per dose); Composition: Xi Yang Shen (Panacis Quinquefolii Radix, 260g), Long Yan Rou (Arillus Longan, 1300g), Shan Yao (Dioscoreae Rhizoma, 1300g), and E Jiao (Colla Corii Asini, 350g); Instruction: It is recommended to take the medication at a fixed time each day.

    Drug: Knee Pain Ejiao Paste

  • Placebo comparator
    Knee Pain Ejiao-free Clear Paste

    Knee Pain Ejiao-free Clear Paste: Oral administration, 1 bag per dose, twice daily (20g per dose); Composition: Xi Yang Shen (Panacis Quinquefolii Radix, 260g), Long Yan Rou (Arillus Longan, 1300g), Shan Yao (Dioscoreae Rhizoma, 1300g), and Mu Tang Chun (Xylitol, 350g)

    Drug: Knee Pain Ejiao-free Clear Paste

Interventions

  • DrugKnee Pain Ejiao Paste

    By comparing Knee Pain Ejiao Paste with the base formula, Knee Pain Ejiao-free Clear Paste, this study minimizes confounding factors such as dosage form, administration method, and matrix components. This approach allows for a precise evaluation of the incremental therapeutic benefits contributed by the addition of Ejiao, thereby providing direct evidence for the medicinal value of Colla Corii Asini.

  • DrugKnee Pain Ejiao-free Clear Paste

    Using an Ejiao-free clear paste as a parallel control.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Numerical Rating Scale (NRS) score for target knee pain at Week 12

    Selection of the target knee joint: For participants with unilateral involvement, the affected knee is designated as the target knee. In cases of bilateral involvement, the knee with the higher Numerical Rating Scale (NRS) pain score will be selected as the target knee. If the pain NRS scores are identical for both knees, the right knee joint will be chosen as the target knee.

    Time frame: Screening Period/Baseline, Week 12

Secondary outcomes

  1. Patient Electronic Diary (ePRO) Joint Pain NRS Score

    During the treatment period, subjects will complete the NRS score for target knee pain and other records on ePRO daily.

    Time frame: Baseline to Week 12

  2. Change from baseline in NRS score for target knee pain at Weeks 4 and 8

    Selection of the target knee joint: For participants with unilateral involvement, the affected knee is designated as the target knee. In cases of bilateral involvement, the knee with the higher Numerical Rating Scale (NRS) pain score will be selected as the target knee. If the pain NRS scores are identical for both knees, the right knee joint will be chosen as the target knee.

    Time frame: Screening Period/Baseline, Week 4, and Week 8

  3. Pain relief rate of target knee pain at Weeks 4, 8, and 12 post-treatment

    Effectiveness is defined as a ≥ 50% decrease in the target knee pain NRS score relative to baseline, where the reduction rate = \[(Pre-trearment score - Post-treatment score) ÷ Pre-trearment score\] × 100%.

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  4. Time to onset of target knee pain relief

    Time (in days) to the first ≥ 25% reduction from baseline in target knee pain NRS score (as recorded in the diary card).

    Time frame: Baseline to Week 12

  5. Change from baseline in WOMAC total score for the target knee at Weeks 4, 8, and 12 post-treatment

    Comparison of the change from baseline in WOMAC total score between groups at Weeks 4, 8, and 12 post-treatment.

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  6. Changes from baseline in WOMAC subscale scores (Pain, Stiffness, and Physical Function) for the target knee at Weeks 4, 8, and 12 post-treatment

    Comparison of the change from baseline in WOMAC subscale scores (Pain, Stiffness, and Physical Function) between groups at Weeks 4, 8, and 12 post-treatment.

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  7. Comparison of MOAKS scores for joint effusion in the target knee at Week 12 post-treatment

    Comparison of the change from baseline in MOAKS joint effusion scores between groups at Week 12 post-treatment.

    Time frame: Screening Period/Baseline, Week 12

  8. Change from baseline in subject satisfaction scores at Week 12 post-treatment

    Comparison of the change from baseline in subject satisfaction scores between groups at Weeks 4, 8, and 12, as well as the proportion of satisfied subjects between groups.

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  9. Change from baseline in investigator satisfaction scores at Week 12 post-treatment

    Comparison of the change from baseline in investigator satisfaction scores between groups at Weeks 4, 8, and 12 post-treatment, as well as the proportion of investigator-rated satisfaction between groups.

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  10. Consumption of rescue medication during the treatment period

    Comparison of the consumption of Celecoxib tablets as rescue medication between groups during the study period.

    Time frame: Baseline to Week 12

  11. Effective rate of TCM syndrome at Weeks 4, 8, and 12 post-treatment

    Comparison of the between-group differences in the effective rate at Weeks 4, 8, and 12 post-treatment. Based on the results of the TCM Syndrome Quantitative Rating Scale, TCM syndrome scores are calculated before and after treatment, and the efficacy is evaluated according to the following criteria: Effective: A reduction in TCM syndrome score of ≥ 50% Ineffective: A reduction in TCM syndrome score of less than 50% The reduction rate of TCM syndrome score is caculated as: Reduction Rate = \[(Pre-trearment score - Post-treatment score) ÷ Pre-trearment score\] × 100%.

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  12. Changes from baseline in TCM syndrome total scores and individual symptom scores at Weeks 4, 8, and 12 post-treatment

    Comparison of the change from baseline in TCM syndrome total scores and individual symptom scores between groups at Weeks 4, 8, and 12 post-treatment.

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

Other outcomes

  1. Adverse Event (AE)

    Adverse events will be evaluated and recorded based on their type, incidence, severity, timing, and causality (relationship to the study drug).

    Time frame: Week 4, Week 8, and Week 12

  2. Vital Signs (Body Temperature)

    Body temperature (°C) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  3. Vital Signs (Pulse Rate)

    Pulse rate (beats per minute, bpm) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  4. Vital Signs (Respiratory Rate)

    Respiratory rate (breaths per minute) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  5. Vital Signs (Blood Pressure)

    Blood pressure (systolic and diastolic, mmHg) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) are recorded and reported separately.

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  6. Laboratory Parameters (Hematology-Red Blood Cell count)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Red Blood Cell count (RBC) Unit: ×10¹²/L (Number of red blood cells per liter of blood × 10¹²)

    Time frame: Screening Period/Baseline, Week 12

  7. Laboratory Parameters (Hematology-White Blood Cell count)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): White Blood Cell count (WBC) Unit: ×10⁹/L (Number of white blood cells per liter of blood × 10⁹)

    Time frame: Screening Period/Baseline, Week 12

  8. Laboratory Parameters (Hematology- Platelet count)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Platelet count (PLT) Unit: ×10⁹/L (Number of platelets per liter of blood × 10⁹)

    Time frame: Screening Period/Baseline, Week 12

  9. Laboratory Parameters (Hematology-Hemoglobin )

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Hemoglobin (HGB)-Hemoglobin Concentration Unit: g/L (grams per liter) or g/dL

    Time frame: Screening Period/Baseline, Week 12

  10. Laboratory Parameters (Hematology-Neutrophil percentage )

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Neutrophil percentage (NEUT%) Unit: % (Percentage of neutrophils among total white blood cells)

    Time frame: Screening Period/Baseline, Week 12

  11. Laboratory Parameters (Liver Function-Alanine Aminotransferase)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Alanine Aminotransferase (ALT) Unit: U/L (units per liter)

    Time frame: Screening Period/Baseline, Week 12

  12. Laboratory Parameters (Liver Function- Aspartate Aminotransferase)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Aspartate Aminotransferase (AST) Unit: U/L (units per liter)

    Time frame: Screening Period/Baseline, Week 12

  13. Laboratory Parameters (Liver Function-Total Bilirubin)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Total Bilirubin (TBIL) Unit: μmol/L (micromoles per liter)

    Time frame: Screening Period/Baseline, Week 12

  14. Laboratory Parameters (Liver Function-Alkaline Phosphatase)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function:Alkaline Phosphatase (ALP) Unit: U/L (units per liter)

    Time frame: Screening Period/Baseline, Week 12

  15. Laboratory Parameters (Liver Function-γ-Glutamyl Transferase)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: γ-Glutamyl Transferase (GGT) Unit: U/L (units per liter)

    Time frame: Screening Period/Baseline, Week 12

  16. Laboratory Parameters (Renal Function- Serum Creatinine )

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Renal Function: Serum Creatinine (Scr) Unit: μmol/L (micromoles per liter) or mg/dL

    Time frame: Screening Period/Baseline, Week 12

  17. Laboratory Parameters (Renal Function- Blood Urea Nitrogen)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Renal Function: Blood Urea Nitrogen (BUN) / Urea Unit: mmol/L (millimoles per liter) or mg/dL

    Time frame: Screening Period/Baseline, Week 12

  18. Laboratory Parameters (Renal Function- Estimated Glomerular Filtration Rate)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Renal Function: Estimated Glomerular Filtration Rate (eGFR) Unit: mL/min/1.73m² (milliliters per minute per 1.73 square meters)

    Time frame: Screening Period/Baseline, Week 12

  19. Laboratory Parameters (Renal Function- Urine Albumin-Creatinine Ratio)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Renal Function: Urine Albumin-Creatinine Ratio (UACR) Unit: mg/g (milligrams per gram) or mg/mmol

    Time frame: Screening Period/Baseline, Week 12

  20. Laboratory Parameters (Urinalysis-Protein )

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Protein (PRO) Unit: Qualitative/Semi-quantitative, typically reported as: Negative (-), Trace (±), +, ++, +++, ++++ (or mg/dL, g/L)

    Time frame: Screening Period/Baseline, Week 12

  21. Laboratory Parameters (Urinalysis-Glucose )

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Glucose (GLU) Unit: Qualitative/Semi-quantitative, typically reported as: Negative (-), Trace (±), +, ++, +++, ++++ (or mmol/L, mg/dL)

    Time frame: Screening Period/Baseline, Week 12

  22. Laboratory Parameters (Urinalysis-Red Blood Cells)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Sediment Microscopy): Red Blood Cells (RBC) Unit: per high-power field (/HPF) or per microliter (μL) (microscope count)

    Time frame: Screening Period/Baseline, Week 12

  23. Laboratory Parameters (Urinalysis-Leukocytes)

    Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Leukocytes (LEU) Unit: per high-power field (/HPF) or per microliter (μL) (microscope count)

    Time frame: Screening Period/Baseline, Week 12

  24. Blood Glucose

    Measuring Fasting Blood Glucose (FBG), which is the blood glucose level measured after fasting for 8 to 12 hours.

    Time frame: Screening Period/Baseline, Week 12

  25. Blood Lipids

    Measuring fasting Total Cholesterol (TC), Low-Density Lipoprotein Cholesterol (LDL-C), High-Density Lipoprotein Cholesterol (HDL-C), and Triglycerides (TG).

    Time frame: Screening Period/Baseline, Week 12

  26. Heart Rate on 12-lead electrocardiogram

    Heart rate (beats per minute) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Unit of Measure: beats per minute (bpm)

    Time frame: Screening Period/Baseline, Week 12

  27. PR Interval on 12-lead electrocardiogram

    PR interval (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Unit of Measure: milliseconds (ms)

    Time frame: Screening Period/Baseline, Week 12

  28. QRS Duration on 12-lead electrocardiogram

    QRS duration (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Monitored for potential ventricular conduction abnormalities. Unit of Measure: milliseconds (ms)

    Time frame: Screening Period/Baseline, Week 12

  29. QT Interval on 12-lead electrocardiogram

    QT interval (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Unit of Measure: milliseconds (ms)

    Time frame: Screening Period/Baseline, Week 12

  30. Corrected QT Interval (QTc) on 12-lead electrocardiogram

    Corrected QT interval (QTc, milliseconds) is calculated from the QT interval on a standard 12-lead electrocardiogram (recorded after ≥5 minutes rest, supine position, calibrated equipment) using Bazett or Fridericia formula as specified in the protocol. Interpreted by qualified cardiologists or trained investigators. Unit of Measure: milliseconds (ms)

    Time frame: Screening Period/Baseline, Week 12

  31. Pharmacokinetic (PK) Parameters-Plasma Maximum Observed Concentration (Cmax)

    Plasma concentration measured from blood samples collected at Baseline, Weeks 4, 8, and 12( or early out of study).The exact time of blood collection and the time of the dose most recent to the collection must be recorded for each visit. Cmax is the maximum observed concentration post-dose. Parameters estimated using non-compartmental analysis or population PK modeling due to sparse sampling. Geometric mean and variability reported. Assessed as an exploratory pharmacokinetic biomarker. Unit of Measure: ng/mL (or appropriate unit, e.g., nmol/L)

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  32. Pharmacokinetic (PK) Parameters-Plasma Trough Concentration (Ctrough)

    Plasma concentration measured from blood samples collected at Baseline, Weeks 4, 8, and 12( or early out of study).The exact time of blood collection and the time of the dose most recent to the collection must be recorded for each visit. Ctrough is the observed minimum concentration at the end of the dosing interval. Reported as geometric mean and variability. Exploratory pharmacokinetic endpoint focusing on steady-state trough exposure. Unit of Measure: ng/mL (or nmol/L, adjust based on drug)

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  33. Pharmacokinetic (PK) Parameters-Time Curve (AUC0-last)

    Area under the concentration-time curve from time zero to the last measurable concentration (AUC0-last), estimated using population PK methods. Geometric mean reported. Exploratory PK biomarker of exposure. Unit of Measure: h·ng/mL (or appropriate, e.g., h·nmol/L)

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  34. Gut Microbial Alpha-diversity

    Evaluation of microbial richness and evenness within fecal samples using 16S rRNA sequencing. Alpha-diversity represents the biological variety within a single sample. Unit of Measure: Shannon Diversity Index (a calculated score typically ranging from 0 to 5, where higher values indicate greater diversity).

    Time frame: Screening Period/Baseline, Week 12

  35. Gut Microbial Relative Abundance

    Assessment of the taxonomic composition of the gut microbiota at the genus and species levels via metagenomic sequencing. Unit of Measure: Percentage of total sequences (%).

    Time frame: Screening Period/Baseline, Week 12

  36. Fecal Metabolomic Profiles

    Untargeted metabolomics analysis using LC-MS/GC-MS to identify global metabolic shifts and differential metabolites induced by the treatment. Unit of Measure: Normalized peak intensity (arbitrary units).

    Time frame: Screening Period/Baseline, Week 12

  37. Fecal Short-Chain Fatty Acid (SCFA)

    Quantitative analysis of major SCFAs (acetate, propionate, and butyrate) using GC-MS. The sum of these concentrations will be reported. Unit of Measure: μ mol/g of feces.

    Time frame: Screening Period/Baseline, Week 12

  38. Plasma Concentration of Cartilage Oligomeric Matrix Protein (COMP)

    Evaluation of cartilage turnover and degradation levels. COMP is a key structural protein of the cartilage matrix, and its plasma concentration reflects the rate of cartilage breakdown in patients with knee osteoarthritis. Measured using Enzyme-Linked Immunosorbent Assay (ELISA). Unit of Measure: ng/mL

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  39. Plasma Level of C-Terminal Cross-Linked Telopeptide of Type II Collagen (CTX-II)

    Assessment of cartilage collagen degradation. CTX-II is a specific biomarker for the degradation of type II collagen, the primary collagen found in articular cartilage. Higher levels are associated with increased radiographic progression of knee osteoarthritis. Measured using high-sensitivity immunoassay. Unit of Measure: pg/mL

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

  40. Plasma Concentration of Tryptophan

    Assessment of systemic amino acid metabolism and inflammatory signaling. Tryptophan is an essential amino acid whose metabolic pathways (such as the kynurenine pathway) are often altered by chronic inflammation in knee osteoarthritis. Changes in tryptophan levels can reflect the metabolic impact of treatment on systemic inflammation and pain-related pathways. Measured using Liquid Chromatography-Mass Spectrometry (LC-MS). Unit of Measure: nmol/L

    Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 43 non-industry phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's planned 9 months is below that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Apr 1, 2026
StartActual
Mar 30, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07504562
Lead sponsor
ShuGuang Hospital
Collaborators
Shanghai University of Traditional Chinese Medicine, DongE E Jiao Coporation Limited
Responsible party
Yuelong Cao (Chief Physician, ShuGuang Hospital) — Principal investigator
First posted
Apr 1, 2026
Start date
Mar 30, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 5, 2026

Study contacts

Yuelong Cao, Ph.D
principal investigator · Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion